Ximedica

In Vitro Diagnostics

Transforming novel biochemical processes into high-value diagnostic platforms

Background:

vivoDx System with Smarticles Technology Disposables
GeneWEAVE

Need:

A simple and elegant workflow to utilize GeneWEAVE’s transformative Smarticles technology on a platform for the prevention and treatment guidance of multidrug-resistant organisms (MDRO). ​

Solution:

The Ximedica and GeneWEAVE teams collaborated on concept development of a revolutionary, low-cost disposable for sample-Smarticle processing and high-sensitivity, automated chemiluminescence detection. Ximedica incorporated their proprietary line of automation components to create a fully automated, continuous (random) access instrument and integrated disposable handling.​

Result:

The collaboration’s success attracted interest from multiple investors and culminated in Roche Diagnostics acquiring GeneWEAVE in 2015 for $425M total consideration.​

The latest in MedTech & Diagnostics straight to your inbox

Stay Informed

At Ximedica, our people define who we are.

More About Our People

Anthony DiBella

Anthony DiBella

Mechanical Engineering Manager

Andre LaFreniere

Andre LaFreniere

VP, Business Development

Betsy Popp

Betsy Popp

Senior Design Assurance Engineer

Manny Resendes

Manny Resendes

Director of Information Technology

Sean McKenna

Sean McKenna

Mechanical Engineer

Jonathan Stokes

Jonathan Stokes

Machinist